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The compound S38151 is a nanomolar antagonist that acts at the melanin-concentrating
hormone receptor 1 (MCH1). S38151 is more stable than its purely peptide counterpart,
essentially because of the blockade of its N-terminus. Therefore, its action on various
models of obesity was studied. Acute intra-cerebroventricular (i.c.v.) administration
of S38151 in wild-type rats counteracted the effect of the stable precursor of
melanin-concentrating hormone (MCH), NEI-MCH, in a dose-dependent manner (from 0.5
to 50 nmol/kg). In genetically obese Zucker fa/fa rats, daily i.c.v. administration of S38151
induced dose-dependent (5, 10, and 20 nmol/kg) inhibition of food intake, water intake, and
body weight gain, as well as increased motility (maximal effect observed at 20 nmol/kg). In
Zucker fa/fa rats, intraperitoneal injection of S38151 (30mg/kg) induced complete inhibition
of food consumption within 1 h. Daily intraperitoneal injection of S38151 (10 and 30mg/kg)
into genetically obese ob/ob mice or diet-induced obese mice is able to limit body weight
gain. Furthermore, S38151 administration (10 and 30mg/kg) does not affect food intake,
water intake, or body weight gain in MCHR1-deleted mice, demonstrating that its effects
are linked to its interaction with MCH1. These results validate MCH1 as a target of interest
in obesity. S38151 cannot progress to the clinical phase because it is still too poorly stable
in vivo.
Keywords: melanin-concentrating hormone, receptors, peptide antagonists, feeding behavior, rat, mice, obesity
models
INTRODUCTION
Melanin-concentrating hormone (MCH) is a 17-amino-acid,
cyclic pseudopeptide that is responsible for the bleaching of skin
in teleost fishes (Kawauchi et al., 1983). In mammals, MCH is
a 19-amino-acid cyclic peptide (Vaughan et al., 1989). Its actions
are not linked to pigmentation, but to a variety of properties, orig-
inally centered on appetite regulation and obesity (Qu et al., 1996;
Pissios et al., 2006). MCH acts in several processes, including
sleep/arousal (Hervieu, 2006; Peyron et al., 2009), emotional-
ity (Hervieu, 2006), and memory (Adamantidis and de Lecea,
2009). MCH is encoded as a pre-pro-hormone, and also gives
rise to two other neuropeptides after proteo-cleavage: (1) neu-
ropeptide N-G (NGE), the function of which is elusive, and (2)
neuropeptide E-I (NEI) (Nahon et al., 1989), which displays vari-
ous functions (Maulon-Feraille et al., 2002; Bittencourt and Celis,
2008). NEI-MCH is more potent than MCH in stimulating feed-
ing in rats, for proteolytic-protective reasons (Maulon-Feraille
et al., 2002). MCH is mainly synthesized in cell bodies of the
lateral hypothalamus and sub-zona incerta in the central ner-
vous system (Bittencourt et al., 1992). MCH is also synthesized
in peripheral organs, such as the gut, arteries, testes, thymus, and
pancreatic β-cells (Hervieu and Nahon, 1995).
Two MCH receptors (MCH1 and MCH2) were identified a
decade ago. MCH1 was known for quite some time as SLC-1, an
orphan receptor in humans (Lakaye et al., 1998). It was estab-
lished as a genuine MCH receptor in 1999 by at least three
different groups (Bachner et al., 1999; Chambers et al., 1999;
Saito et al., 1999). The subsequent search for analogs of the pro-
tein led to the cloning of a second receptor, MCH2 (Mori et al.,
2001; Rodriguez et al., 2001; Sailer et al., 2001; Wang et al., 2001).
This second receptor is expressed in humans, dogs, and ferrets,
but not in rodents. In mammalian species, the highest expression
levels of both receptors are found in the frontal cortex, amyg-
dala, and nucleus accumbens; however, they are also expressed in
hypothalamic areas regulating energy balance, such as the arcuate
nucleus and the ventral medial hypothalamus. MHCRs are also
moderately expressed in peripheral organs. In rodents, MCH acts
through MCH1, which implicates MCH1 in obesity and energy
homeostasis.
Several genetically engineered strains of mice have been
reported. MCH1-knockout (MCH1-KO) mice (mice do not
express a functional MCHR2 protein) exhibit a phenotype
of leanness and resistance to diet-induced obesity, charac-
terized by hyperphagia, hyperactivity, and hypermetabolism
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(Chen et al., 2002; Marsh et al., 2002; Pissios, 2009). This
phenotype is attributed to increased energy expenditure, result-
ing from increased locomotor activity and increased resting
energy expenditure. Paradoxically, these mice exhibit significant
hyperphagia.
The molecular pharmacology of MCH1 has been studied in
some detail. After the centrally important works of teams at
Takeda and Synaptic/Lundbeck (Borowsky et al., 2002; Takekawa
et al., 2002), many non-peptide compounds were screened and
found active at MCHR1. Most of these small molecules inhibit
MCH-mediated feeding behavior; however, they may also affect
energy expenditure. Interestingly, MCH1 antagonists of differ-
ent chemical classes exhibit anxiolytic and anti-depressant effects,
a finding that would likely contribute to the success of these
molecules in obese populations that might also have depres-
sion and anxiety. However, cardiovascular risk associated with
human ether-a-go-go-related gene (hERG)-binding activity of
biaryl-containing compounds has plagued many of these non-
peptide MCH1 antagonist programs (Mendez-Andino and Wos,
2007; Meyers et al., 2007; Johansson, 2011).
Alternatively, several dozen MCH analogs have been synthe-
sized and tested by binding, leading to the discovery of pep-
tide super-agonists and mild antagonists. Some of these have
been tested on MCH2, and present major selectivity to MCH1.
Structure activity relationship is now well-established concerning
the peptide ligands. Although small molecules had been synthe-
sized as potent and moderately selective MCH1antagonists, there
was still an interest in finding new peptides with antagonistic
activities. Pioneering works by Bednarek’s group described such
interesting compounds. In agreement with our initial search for
better agonists (Audinot et al., 2001a,b), we explored the possibil-
ity of designing natural peptides or pseudopeptides [pseudopep-
tides are peptides including one or more exotic aminoacid(s) in
their sequence] with good MCH1 antagonism and fair in vivo
stability. We succeeded in describing S38151 (Audinot et al.,
2009), a potent peptide at MCH1 with antagonistic activity in
the nanomolar range. The aim of the present study was to
evaluate the possible inhibition of S38151 on food and water
intakes, body weight, and motility after one-time or repeated
daily peripheral administration in different rodent models of obe-
sity. Confirmation of the MCH1-mediated actions of S38151 was
tested in mice with genetic ablation of the receptor. Mice with
genetic ablation of MCH1were used to confirm that the tran-




MCH and S38151 (Audinot et al., 2009) were obtained from
Polypeptide Laboratories (Illkirch, France) and/or from Genepep
(Saint Jean de Védas, France). They were of purity exceed-
ing 97%. S38151 is a pseudopeptide, the sequence of which
is: [p-guanidinobenzoyl-(Des-Gly10)-MCH (7–17)], or pGua-
Cys-Met-Leu-Arg-Val-Tyr-Arg-Pro-Cys; both cysteines are linked
together with a disulfide bridge. The molecular weight of S38151
is 1485 g/L. All of the various lots were systematically analyzed
using mass spectrometry.
S38151 STABILITY STUDIES
First, S38151 was incubated for 16 h at 4◦C and 37◦C in mouse
plasma or in TRIS buffer (pH 7.4). Next, plasma proteins were
precipitated with two volumes of acetonitrile. After centrifu-
gation and dilution with a water/acetonitrile mixture (50/50
v/v), the supernatant was injected onto a triple quadripole
mass spectrometer (Ultima, Micromass WATERS Corporation,
Milford, USA). The liquid chromatographic system consisted
of an Agilent 1100 analytic pump (Agilent, Santa Clara, USA)
equipped with an Alpha Mos CTC autosampler (Alpha Mos,
Toulouse, France). Mass detection was performed using the m/z
transition 743.5 > 163, in positive electrospray. A second stabil-
ity study was performed at a lower concentration (1μM) and
for 4 h, with the following sampling times: 0, 15, 45, 90, and
240min. At each sampling time, 50μL of plasma were precipi-
tated with two volumes of acetonitrile, and after centrifugation
were directly injected onto the LC-MS/MS system. The same
treatment was used for the buffer samples. Although brains from
S38151-treated animals were analyzed to determine the amount
of compound detectable in the brain, none was detected (data
not shown).
ANIMALS
These experiments were conducted with male Wistar and Zucker
fa/fa rats (10–13 weeks of age, weighing 325–350 g) together
with C57BL/6J mice, ob/ob mice, and MCH1-KO mice (14 weeks
of age, weighing 25, 45, and 25 g, respectively) (Iffa Credo and
Charles River, L’Arbresle, France). The animals were housed indi-
vidually in a room with a 12-h light/dark cycle (lights on at 07:30
and off at 19:30), at 22 ± 3◦C and 55% relative humidity. Normal
food and tap water were available ad libitum unless otherwise
stated. All animal procedures described in this study comply with
French laws regulating animal experimentation (Decree No 87-
848 19th October 1987 and the ministerial Decree of 10 April
1988) and were approved by the animal ethics committee of the
Servier Research Institute.
INTRA-CEREBROVENTRICULARCANNULA IMPLANTATION
Acute i.c.v. injections in rats
Wistar and Zucker fa/fa rats were anesthetized with Forène
(Abbott Laboratories, Queenborough, UK), and a stainless steel
guide cannula (Plastic Products Co, Roanoke, Va, USA) was
stereotaxically implanted into the right lateral ventricle at the
following coordinates relative to the bregma: AP −0.8mm,
L = − 1.2mm, and V = −3.5mm. After a 7-day recovery
period, during which the animals were handled each day to
minimize non-specific stress, they were lightly anesthetized with
Forène. Human/mouse/rat MCH (1μg in a volume of 2.5μL,
Bachem, Voisins-le-Bretonneux, France) or an equivalent volume
of artificial cerebrospinal fluid (CSF) was then injected through
the intraventricular cannula. Immediately after injection, the ani-
mals quickly recovered and were returned to their home cages.
Only those animals responding within 2 h with a robust increase
in food intake, indicating correct cannula placement, were used in
the experiments described below. Two days after MCH injection,
the rats were randomly assigned to different groups and studied
in one of the following protocols.
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Acute central peptide administration and feeding studies in
Wistar rats
Wistar rats were habituated for at least 2 weeks before experiment
to a diet of food pellets (6mm diameter) of the following com-
position: 67.5% food flour, 26.5% sucrose, 5% gum tragacanth,
and 1.25% magnesium stearate (A03 UAR, Orge, France). The
food pellets were present in a metal food hopper attached to the
inside of each cage. At 09:00 on the day of study, the animals were
lightly anesthetized with Forene® (Abbott, France). Thereafter,
rats were injected intra-cerebroventricular (i.c.v.) with vehicle
(artificial CSF) or with S38151 [0.5, 5, 10, 20, 30, or 50 nmol/kg
(0.7, 1.4, 14, 28, 42, or 70μg/kg, respectively)] in a volume of
2.5μL, 20min prior to the injection of human/rat NEI-MCH
[5 nmol/kg (18.7μg/kg) in a volume of 2.5μL].
Food intake was measured at different times after peptide
injection. Food spillage was carefully quantified during each time
period, and intake measurements were corrected for this loss. At
the end of the experiments, the animals were euthanized and the
positions of the cannulae were assessed by the injection of 100μL
Evans blue dye (2mg/mL) followed by the visual examination
of brain slices. Only data obtained from animals with correctly
positioned cannulae were included in the final data analysis.
Daily central peptide administration and feeding studies in
Zucker rats
The TSE Drinking and Feeding Monitor system was used to
analyze ingestive behavior in these experiments (TSE Technical
& Scientific Equipment GmbH, Bad Homburg, Germany). The
rats’ motility was also determined in these experiments using the
MoTil® system (TSE). Zucker fa/fa rats were placed individually
into plastic cages to which were attached both a feeding and a
drinking sensor. The animals were habituated to normal food
(A03 UAR, Orge, France) and water for at least 2 weeks before
experimentation. One hour prior to the beginning of the dark
phase, Zucker fa/fa rats were injected i.c.v. with different doses of
S38151 [5, 10, or 20 nmol/kg (3.5, 14, or 28μg/kg, respectively)]
or with an equivalent volume of artificial CSF vehicle (10μL).
The injections were repeated daily for a total of 7 days. After 7
days, the injections were stopped and each measured parameter
was followed during a 5-day washout period.
ACUTE PERIPHERAL PEPTIDE ADMINISTRATION AND FEEDING
STUDIES IN ZUCKER RATS
Zucker fa/fa rats were habituated in the same conditions asWistar
rats (described in section “Acute Central Peptide Administration
and Feeding Studies in Wistar Rats”). At 09:00 on the day of
study, after fasting for 24 h, either vehicle (normal saline) or
S38151 [30mg/kg (20μmol/kg)] was administered intraperi-
toneally (i.p.).
CONDITIONED TASTE AVERSION
These experiments were performed according to previously
described methods (Criscione et al., 1998; Welzl et al., 2001). In
brief, Wistar rats were individually housed in plastic cages with
free access to normal food and water. During a 7-day habituation
period, the water bottle was removed from the cages overnight
(from 16:00 to 10:00). At 10:00, water was made available to the
animals from 250-mL plastic bottles to which a normal drink-
ing spout was attached. The bottles were weighed before and after
presentation to the animals to determine the quantity of water
ingested during this period. After 4 days of this treatment regime,
which served to habituate the animals to the experimental proto-
col and to randomize the animals, 0.2% saccharine was presented
instead of water. Twenty minutes after the test period, the ani-
mals were injected i.p. with lithium chloride (75mg/kg) or i.c.v.
with S38151 [20 nmol/kg (28μg/kg)] or vehicle (artificial CSF).
Four, 7, 11, and 14 days later, the consumption of saccharine was
determined. Considerable care was taken in these experiments to
first prevent and then quantify any leakage of saccharine solution
during the presentations.
PICA
These experiments were performed with modifications to pre-
viously described methods (Madden et al., 1999). Rats were
individually housed in wire-bottomed plastic cages with free
access to both food pellets (6mm diameter A03 UAR) and kaolin
powder. The food pellets were presented in a small porcelain
bowl on the floor of the cage. The kaolin powder was pre-
sented in a metal feeding dish attached to the inside of the
cage. After a 2-week habituation period to these conditions, the
animals were randomized into five treatment groups based on
the quantity of food eaten during the stabilization period. In
addition, those rats that consistently spilled the kaolin powder
were eliminated from the study. One day after randomization,
the animals were injected just before the beginning of the dark
phase with either cyclophosphamide (100mg/kg, i.p.), or S38151
[20 nmol/kg (28μg/kg) i.c.v.] or vehicle [(artificial CSF) i.c.v.].
After injection, the quantity of kaolin and food ingested during
the following 24-h period was determined. Food or kaolin spilled
by the animals was collected at the end of the experiment, and
total food and kaolin intake measurements were corrected for
this loss.
CONSTRUCTION OF MCHr1−/− MICE
Construction of the targeting vector
The MCHR1−/− mouse model was custom-constructed by
genOway (Lyon, France). The construction of the targeting
vector and knock-in strategy were designed and performed
by genOway (Lyon, France). A genomic clone containing the
murine Mchr1 locus was isolated from a C57BL/6J RPCI-24
BAC genomic library by using a probe corresponding to the
murine Mchr1 exon 2: one BAC clone (544N15) containing the
Mchr1 locus. The genomic organization of the targeted locus
was determined by subcloning the XhoI-SpeI genomic fragment
into the pZErO™-2 vector (Invitrogen, Carlsbad, California).
The 7.4-kb XhoI-SpeI genomic insert was sequenced and the
Mchr1 sequence was generated. The genomic clone (contain-
ing the entire gene) was used to construct the targeting vector.
Briefly, a 5.1-kb XhoI/ApaI fragment comprising Mchr1 exons
1 and 2 and a 1.1-kb ApaI/BglII fragment located downstream
of Mchr1 exon 2 were used to flank a NEO cassette (FRT-PGK
promoter-NeoR cDNA-FRT-LoxP) (Figure 1A); a negative (DTA)
selection cassette was introduced at the 5′ end of the long arm of
homology.
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FIGURE 1 | Construction of MCHR1−/− mice. (A) Strategy for the
construction of MCHR1−/− mice. The Mchr1 locus (containing
exons 1–2) and the targeting construct [containing the neomycin
(PGK-Neo) cassette with flanking segments homologous to the locus]
are shown. The probe used in all Southern blot analyses was a 0.65-kb
fragment located in a region upstream of exon 1. (B) Southern blot
analysis of the offspring of MchR1-deleted mice, compared with
C57BL/6J mice. Digestion of tail DNA with AvrII/SacII resulted in the
following diagnostic fragments: a wild-type band (4.2kb), and a deleted
allele band (6.6 kb).
Screening of Mchr1-recombined ES cell clones
NotI-linearized targeting vector was transfected into 129SvPas
ES cells (genOway, Lyon, France) according to genOway’s mod-
ified electroporation procedures (i.e., 108 ES cells in the presence
of 100μg of linearized plasmid, 800 V, 300μF). Positive selec-
tion was started 48 h after electroporation, by adding 200μg/mL
of G418 (150μg/mL of active component, Life Technologies,
Inc.). A total of 333 resistant clones were isolated and ampli-
fied in 96-well plates, and duplicates were made of the 96-well
plates. The set of plates containing ES cell clones amplified on
gelatin was screened by PCR and further confirmed by Southern
blotting.
5′ PCR screening conditions were: GW676 primer specific for
a region upstream of Mchr1 exon 1 (5′-GATATCAATTCGGGA
CACATGG-3′) and GW681 primer specific for the NeoR selec-
tion cassette (5′-TCTCGGCAGGAGCAAGGTGAGATGACAG-
3′). PCR conditions were 94◦C/2min, and 35 cycles of (94◦C/30 s,
59◦C/30 s, and 68◦C/6min) followed by 68◦C/10min, resulting
in a 6509-bp mutated allele. 3′ PCR screening conditions were:
GW668 primer specific for the Neo® selection cassette (5′-ATCA
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GGACATAGCGTTGGCTAC-3′) and GW669 primer to hybridize
the region downstream of the Mchr1 gene (5′-ATGAGAAGTG
ACCAGCAAGAGC-3′). PCR conditions were 94◦C/2min, and
35 cycles of (94◦C/30 s, 61◦C/30 s, and 68◦C/2min), followed
by 68◦C/10min, resulting in a 1609-bp recombined allele. Both
PCR reactions were performed using Long Expand High Fidelity
polymerase (Roche®) and reaction buffer 3. PCR products were
then digested with PmeI to confirm the integration of the distal
loxP site within the recombined allele. Briefly, for Southern blot
analysis, genomic DNA was digested with AvrII/SacII and then
hybridized with a 0.65-kb probe; Mchr1 ± clones gave rise to a
4.2-kb wild-type signal and 5.6-kb recombined signal.
In vitro Cre-mediated deletion of Mchr1-recombined ES cell clones
Two recombined ES cell clones were used to perform Cre-
mediated deletion of the floxed Mchr1 region. Supercoiled Cre-
expressing plasmid was transfected into Mchr1-recombined ES
cells (genOway, Lyon, France) according to genOway standard
procedures. No selection was applied. One hundred ES cell
clones were isolated and amplified in 96-well plates, and dupli-
cates were made of the 96-well plates. The set of plates con-
taining ES cell clones amplified on gelatin was screened by
PCR and further confirmed by Southern blotting. The PCR
screening conditions were: GW787 primer specific for Mchr1
exon 1 (5′-AGCTCTGAAGGAGAAGGGAATG-3′) and GW669
primer to hybridize the region downstream of the Mchr1 gene
(5′-ATGAGAAGTGACCAGCAAGAGC-3′). The PCR conditions
were 94◦C/2min, and 35 cycles of (94◦C/30 s, 59◦C/30 s, and
68◦C/6min), followed by 68◦C/10min, resulting in a 4481-bp
recombined allele and a 1564-bp deleted allele. The PCR reac-
tion was performed using Long Expand High Fidelity polymerase
(Roche®) and reaction buffer 3. Briefly, for Southern blot analysis,
genomic DNA was digested with AvrII/SacII and then hybridized
with a 0.65-kb probe. The Mchr1 wild-type allele gave rise to a
4.2-kb signal, the Mchr1-recombined allele gave rise to a 5.6-kb
signal, and the Mchr1 deleted allele gave rise to a 6.6-kb signal.
Generation of chimeric mice and breeding scheme
One floxed mutated Mchr1 ES cell clone (clone #2A9-2A10)
was microinjected into C57BL/6J blastocysts, and gave rise to
male chimeras with a significant ES cell contribution (as deter-
mined by Agouti coat color). After mating with C57BL/6J
females, germline transmission was confirmed by the geno-
typing of tail DNA from offspring using PCR and Southern
blot analysis. Knock-out heterozygous animals were screened as
described in section “Screening of Mchr1-Recombined ES Cell
Clones.” PCR screening conditions were: GW787 primer specific
for Mchr1 exon 1 (5′-AGCTCTGAAGGAGAAGGGAATG-3′) and
GW669 primer to hybridize the region downstream of the Mchr1
gene (5′-ATGAGAAGTGACCAGCAAGAGC-3′). PCR conditions
were 94◦C/2min, and 35 cycles of (94◦C/30 s, 59◦C/30 s, and
68◦C/6min), followed by 68◦C/10min, resulting in a 3.1-kb sig-
nal for the wild-type allele and 1.6-kb signal for the deleted
allele. The PCR reaction was performed using Long Expand
High Fidelity polymerase (Roche®) and reaction buffer 3. Briefly,
for Southern blot analysis, genomic DNA was digested with
AvrII/SacII and then hybridized with a 0.65-kb probe. The wild-
type Mchr1 allele gave rise to a 4.2-kb signal and the deleted
Mchr1 allele gave rise to a 6.6-kb signal (Figure 1B). F1 male and
female heterozygous animals were interbred to obtainMchr1-null
mice, and offspring were also screened by PCR and Southern blot
analysis as described in this section.
FOOD INTAKE IN C57BL/6J AND ob/ob MICE
For the MCH daily repeated i.c.v. injection studies, 13-week-old
female C57BL/6J and ob/ob mice were used (Harlan, Gannat,
France).
FOOD INTAKE INDUCED OBESITY IN C57BL/6J, ob/ob, AND
MCHr1-KO MICE
In these studies, 13-week-old female C57BL/6J, ob/ob, and
MCH1-KO mice were used. The mice were maintained on a 12-h
light/dark cycle (lights on at 07:30 and off at 19:30) at 22 ±
3◦C, and supplied with food pellets (6mm diameter A03, UAR
Laboratory chow, Epinay Villemuisson France) and tap water
ad libitum. To induce obesity in C57BL/6J (creating diet-induced
obese, or DIO, mice), mice were fed a high-fat diet (60 kcal%
fat, 20 kcal% protein, 20 kcal% carbohydrate, ref D12492 from
Research Diets, New Brunswick, NJ08901, USA) for 8 weeks start-
ing at 4 weeks of age. In these experiments, DIO mice, ob/ob
mice, and MCH−/−1 mice were individually housed in a modular
chamber that was placed on an activity platform to concurrently
measure the food intake, water intake, and activity of the mice
(ADDENFI, Les Cordeliers, Paris, France). For at least 2 weeks
before experimentation, mice were habituated to a diet of 6mm
diameter food pellets of the following composition: 67.5% food
flour, 26.5% sucrose, 5% gum tragacanth, 1.25% magnesium
stearate (A03 UAR, Orge, France), and to i.p. injection. After this
habituation period, food intake, drink intake, and body weight
were measured for 3 consecutive days. The mice were random-
ized into three groups based on their food and water intake over
the three preceding 24-h periods, and on their body weight. Next,
the quantity of food eaten over each 24-h period during the 5
days of i.p. treatment with S38151 [10 and 30mg/kg/day (7 and
20μmol/kg/day)] or vehicle was determined and corrected for
spillage.
DATA AND STATISTICAL ANALYSIS
Data were grouped together and presented as mean ± standard
error (SEM). The individual statistical tests that were used in these
studies are described in detail in the figure legends. In each case,
P-values less than 0.05 were considered statistically significant.
RESULTS
S38151 CHARACTERISTICSAND SERUM STABILITY
S38151 was synthesized during a process that was attempting to
find peptides or pseudopeptides with affinity at MCH1 receptor
that also had greater stability in biological media. This pseu-
dopeptide is derived from another, very similar agonist, pGua
(MCH7-17) (Audinot et al., 2001a, 2009). In Chinese hamster
ovary cells over-expressing MCH1, S38151 exhibited a Ki of
80 nM in a [125I]-S36057 binding assay and was a potent and
full antagonist (KB = 4.3 nM in a GTPγS binding assay, and
KB = 210 nM in a calcium flux assay) (Audinot et al., 2009).
This activity was specific to MCH1, since it has no activity with
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respect to MCHR2 at concentrations of less than 10μM. This
compound was also evaluated on a series of 70 targets, compris-
ing monoaminergic and peptidergic receptors as well as enzymes,
ionic channels, and transporters. S38151 did not display any
activity regarding these targets at concentrations of less than
10μM (data not shown). The peptide was incubated either in a
buffered solution (pH 7.4) or in mouse plasma for 16 h, at either
4◦C or 37◦C. Figure 2 clearly shows that at 37◦C, a minimal por-
tion of S38151 is detectable, suggesting that it has limited stability
in plasma.
THE EFFECT OF A SINGLE i.c.v. INJECTION OF S38151 ON
NEI-MCH-INDUCED FOOD INTAKE IN WISTAR RATS
The acute effects of a single i.c.v. injection of S38151 on
NEI-MCH-induced food intake in Wistar rats are summarized
in Figure 3. During the first 2 h after its injection, NEI-MCH
produced a significant increase in food intake above the cor-
responding values observed in vehicle-injected control animals
(T1h: 3.18 g ± 1.09 vs. 0.45 g ± 0.19; T2h: 2.73 g ± 0.89 vs.
1.25 g ± 0.38). Relative to control values, the increase in food
intake induced by NEI-MCH became progressively greater dur-
ing the following 4-h period (from T1 h to T4 h). During the
first and second hours, the MCHR1 antagonist S38151 pro-
duced a statistically significant dose-related inhibition of the
increase in food intake produced by NEI-MCH. Nearly com-
plete inhibition of NEI-MCH-induced food intake was observed
at the dose of 50 nmol/kg S38151. Thereafter, for each dose of
S38151, food intake increased essentially in parallel with the food
increase in the NEI-MCH-treated group. Food intake during
the entire 24-h period in the control group was not signifi-
cantly altered by NEI-MCH, or by any combination of NEI-MCH
and S38151.
THE EFFECTS OF DAILY S38151 i.c.v. INJECTIONS ON FOOD INTAKE,
BODY WEIGHT, ANDMOTILITY IN ZUCKER fa/fa RATS
The effects of daily S38151 i.c.v. injection on themeasured param-
eters are depicted in Figure 4. During the 7-day experimental
FIGURE 2 | Studies regarding the stability of S38151. A solution of
S38151 (40μM) was incubated with either Tris buffer, pH 7.4 (hatched bars),
or mouse plasma samples (dark bars) for 16h at 4◦C or 37◦C. The samples
were analyzed using liquid chromatography coupled to mass spectrometry.
Experiments were repeated three times. The chart presented is
representative of the experimental results.
period, injection of 28μg/kg (5 nmol/rat) S38151 1 h before the
dark phase resulted in dose-dependent inhibition of food intake.
However, the change in food intake only reached statistical signif-
icance at the dose of 20 nmol/kg (28μg/kg) S38151. Immediately
after the injections were terminated, food intake returned to
control levels for the duration of the washout period.
In contrast to food intake, water consumption appeared to be
more sensitive to inhibition of MCHR1; water intake was sig-
nificantly inhibited in response to all injected doses of S38151
except for the 5 nmol/rat dose. Immediately after the injections
were terminated, water intake returned to control levels during
the washout period. In a manner similar to water intake, motility
also appeared to be more sensitive to the effects of MCH1 block-
ade; motility was significantly increased at both the 10 nmol/kg
and 20 nmol/kg doses of S38151. Notably, the increase in motility
was not terminated after the S38151 injections were stopped. This
finding was most marked during the washout period after admin-
istration of the 20 nmol/kg dose of S38151, during which motility
remained significantly elevated. During the 7-day experimental
period, S38151 produced a dose-dependent reduction in body
weight gain compared with control rats at the 10 and 20 nmol/kg
doses. After the injections were stopped, body weight gain exhib-
ited a tendency to return to control values. However, body weight
gain remained significantly less than control values during the
washout period after injection of 10 nmol/kg S38151.
FIGURE 3 | The effect of S38151 on NEI-MCH-induced food intake in
Wistar rats after acute central administration. Satiated rats were
injected (i.c.v.) at the beginning of the light phase with 5μg NEI-MCH,
5μg NEI-MCH + differing doses of S38151 (0.5–50nmol/kg), or an
equivalent volume of artificial cereblospinal fluid vehicle (5μL). Cumulative
food intake was measured at 1, 2, 4, 6, and 24h post-injection. Results
are expressed as mean ± SEM (n = 10–11 rats per group). Repeated
measures Two-Way ANOVA (treatment × time) was followed by post hoc
Student-Neuman-Keuls analysis to compare all groups of animals.
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FIGURE 4 | The effects of repeated daily central administration of
S38151 on food intake, water intake, body weight, and motility in
Zucker fa/fa rats. One hour prior the beginning of the dark phase,
different doses of S38151 (5, 10, or 20nmol/kg) or vehicle were injected
(i.c.v.) once daily for 7 days, followed by a washout period of 5 days.
Results are expressed as mean ± SEM (n = 8 rats per group). Repeated
measures Two-Way ANOVA (treatment × time) was performed with a
repeated measure of the factor “time.” Significant treatment and
interaction effects are shown on the graph. +P < 0.05; ++P < 0.01;
+++P < 0.001.
THE EFFECTS OF S38151 ON CONDITIONED TASTE AVERSION AND PICA
IN ZUCKER fa/fa RATS
The results of the conditioned taste aversion test are shown
in Figure 5A. The consumption of 0.2% saccharine during the
first exposure (test day 0) before treatment was well matched
between the three groups. Subsequent injection of lithium chlo-
ride resulted in a significant reduction in 0.2% saccharine con-
sumption during test days 4, 7, 11, and 14 compared with the
control group. In contrast, S38151 injection did not affect 0.2%
saccharine consumption.
In the Pica test, vehicle-injected control animals ate 27 ± 1 g
of normal food and very little kaolin (0.05 ± 0.01 g) during the
24-h experimental period (Figure 5B). Cyclophosphamide (i.p.
injection) resulted in the nearly complete suppression of spon-
taneous food intake, which was accompanied by a significant
increase in kaolin intake. In contrast, i.c.v. injection of S38151
[20 nmol/kg (28μg/kg)] significantly reduced food intake but did
not significantly alter kaolin intake compared with control values.
THE EFFECT OF A SINGLE i.p. INJECTION OF S38151 ON FOOD INTAKE
IN FASTED ZUCKER fa/fa RATS
The acute effect of i.p.-injected S38151 on food intake in Zucker
fa/fa rats is summarized in Figure 6. After a 24-h period of
food restriction, rats ate 3.6 ± 0.4 g during the first hour after
the food pellets were put back. S38151 (i.p. injection) at the
dose of 30mg/kg (approximately 60 nmol/rat) 1 h before re-
feeding induced a dramatic fall in food intake from the first hour
(0.09 ± 0.06 g) to 6 h compared with the control group. This
decrease maintained statistical significance up to 24 h after drug
administration.
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FIGURE 5 | The effects of S38151 on conditioned taste aversion and pica
in Zucker fa/fa rats. (A) In the conditioned taste aversion test, after a period
of habituation of the animals to the experimental protocol, Zucker fa/fa rats
were presented with 0.2% saccharine for 20min after drinking water was
removed from their cages for 18h (test day 0). Animals were then injected
(i.p.) with vehicle or lithium chloride, or with S38151 (20nmol/kg, i.c.v). On
test days 4, 7, 11, and 14, rats were presented with 0.2% saccharine, and the
quantity consumed during a 20-min period was determined. Results are
expressed as mean ± SEM (n = 10–11 rats per group). Repeated measures
Two-Way ANOVA (treatment × time) was followed by post hoc
Student-Neuman-Keuls analysis to compare all groups of animals.
++P < 0.01, +++P < 0.001. (B) In the pica test, Zucker fa/fa rats were
injected (i.c.v.) with 20nmol/kg S38151, or an equivalent volume of artificial
cerebrospinal fluid vehicle. Food and kaolin intake during the following 24-h
period were each measured. Results are expressed as mean ± SEM
(n = 8 rats per group). One-Way ANOVA was followed by Dunnett’s test,
which compared the treated group with the control group. +P < 0.05,
+++P < 0.001.
THE EFFECTS OF DAILY i.c.v. INJECTION OF MCH ON FOOD INTAKE
AND BODYWEIGHT IN ob/ob MICE
Food intake
Food intake in vehicle-infused C57BL/6J mice ranged from 3
to 4 g/day during the 5-day experimental period (Figure 7A).
Infusion of MCH at 5μg/mouse/day (100 nmol/kg/day) resulted
in a sustained and significant increase in food intake above the
values observed in vehicle-infused mice on day 5 ( = +1.3 g vs.
controls). Food intake in ob/ob mice (Figure 7C) ranged from 3.5
to 5 g/day during the experimental period, and was significantly
greater than that observed in C57BL/6J mice. Infusion of MCH at
5μg/mouse/day in ob/ob mice significantly increased food intake
above the values obtained in vehicle-infused control animals. The
increase in food intake produced by MCH infusion in ob/ob mice
on day 5 was significantly greater than that observed in lean mice
( = +3.2 g vs. controls).
Body weight
In C57BL/6J mice, body weight remained stable during the 5-day
experimental period (Figure 7B). Infusion of MCH resulted in
a significant increase in body weight on day 5 ( = +1.3 g vs.
controls). Body weight tended to decrease slightly during the
experimental period in vehicle-infused ob/ob mice (Figure 7D).
However, infusion of MCH reversed this trend, and body weight
had increased significantly above control levels after 5 days of
treatment ( = +2.1 g vs. controls). The increase in body weight
in MCH-infused ob/ob mice on day 5 was significantly greater
than that observed in either group of lean mice.
THE EFFECTS OF DAILY S38151 i.p. INJECTION ON FOOD ANDWATER
INTAKE, BODYWEIGHT, ANDMOTILITY IN ob/ob MICE
The effects of daily i.p. injection of S38151 on the measured
parameters are depicted in Figure 8. During the 6-day exper-
imental period, i.p. injection of S38151 1 h before the dark
phase produced a dose-dependent inhibition of food intake that
reached significance starting on day 3 only at the highest dose
of 30mg/kg (20μmol/kg/day). Water intake presented the same
profile, but did not reach statistical significance because of the
greater variability in water consumption among mice. During the
6-day experimental period, S38151 produced a dose-dependent
reduction in body weight compared with control mice, with
the 30mg/kg dose reaching statistical significance at days 1, 4,
5, and 6. In contrast, motility appeared to be similar among all
groups. On day 6, an improvement of metabolic parameters (sig-
nificant reductions in glycemia and insulinemia) was observed at
a dose of 30mg/kg (data not shown).
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FIGURE 6 | The effect of S38151 on food intake in Zucker fa/fa rats
after acute peripheral administration. Rats were fasted for 24h, and then
injected (i.p.) at the beginning of the light phase with vehicle (normal saline)
or 30mg/kg S38151. Cumulative food intake was measured 1, 2, 4, 6, and
24h after injection. Results are expressed as mean ± SEM (n = 16 rats per
group). Repeated measures Two-Way ANOVA (treatment × time) was
followed by post hoc Student-Neuman-Keuls analysis to compare all groups
of animals. +P < 0.05.
THE EFFECTS OF DAILY i.p. INJECTION OF S38151 ON FOOD INTAKE,
BODYWEIGHT, AND MOTILITY IN DIO MICE
The effects of daily i.p. injection of S38151 on the mea-
sured parameters are depicted in Figure 9. During the 5-day
experimental period, i.p. injection of S38151 1 h before the dark
phase produced a dose-dependent inhibition of food and drink
intake that reached significance beginning on day 2 only at the
30mg/kg dose. A reduction in body weight gain was observed at
the 10 and 30mg/kg doses (7 and 20μmol/kg/day, respectively),
which reached statistical significance at day 3 and day 1, respec-
tively, compared with control mice. S38151 induced a similar
significant reduction inmotility at the two tested doses from day 3
to day 5. At day 6, an improvement of metabolic parameters (sig-
nificant reductions in glycemia and insulinemia) was observed
at a dose of 30mg/kg (data not shown). In another experiment,
daily i.p. administration of 30mg/kg S38151 for 16 days induced
a significant reduction of body weight gain that was accompa-
nied by reduced glycemia and insulinemia, as well as a significant
reduction of triglycerides, free fatty acids, and fat mass (data not
shown).
THE EFFECTS OF DAILY i.p. INJECTION OF S38151 ON FOOD INTAKE,
BODYWEIGHT, AND MOTILITY IN MCH1-KO MICE
During the 5-day experimental period, i.p. injection of S38151 1 h
before the dark phase did not induce any significant effects on the
food intake, drink intake, or body weight of MHCR1-KO mice;
however, a significant reduction in motility was observed at the
highest dose of 30mg/kg (20μmol/kg/day) (Figure 10).
DISCUSSION
In the present study, we have investigated the effects of a selec-
tive MCH1 peptide antagonist, S38151 (Audinot et al., 2001a,
2009), on food intake, drinking, body weight, and/or motility in
lean rats and mice, as well as in Zucker fa/fa rats, ob/ob mice,
and DIO mice. Central acute administration of S38151 inhib-
ited proMCH131-165 (MCH-NEI peptide)-induced feeding in
lean animals in a dose-dependent manner. This effect lasted for
over 6 h, in agreement with the estimated concentration of com-
pound still present in plasma. In several obese rodent models
(7-day treatment in Zucker fa/fa rats, 6-day treatment in ob/ob
mice, and 5-day treatment in DIO mice), S38151 produced a
robust and dose-dependent reduction in food intake and body
weight gain. Drinking behavior was also inhibited in Zucker
fa/fa rats and DIO mice. However, the cessation of S38151 injec-
tions resulted in a rapid resumption of feeding and drinking
behaviors in Zucker fa/fa rats, a transitory action that greatly con-
trasted with the persistent weight loss. Repeated daily blockade
of MCH1 receptors with S38151 reduced food intake and body
weight with attenuated magnitude in leptin-deficient ob/ob mice
relative to that observed in DIO mice. This observation was also
reported with another MCH1 antagonist (Kowalski et al., 2006),
presumably owing to the emergence of multiple alterations in
leptin-responsive neuronal pathways implicated in the feeding
behavior of ob/ob mice.
To clearly establish the involvement of MCH1 in the mode
of action of S38151 on feeding and weight controls, its effects
were evaluated in MCH1-KO mice. Consistent with direct MCH1
antagonism, S38151 did not produce any significant effect on
feeding, drinking, or body weight gain in MCH1-KO mice
treated for 5 days. Combined with the growing literature on
MCH1 antagonists (see reviews Mendez-Andino and Wos, 2007;
Johansson, 2011), these data strengthen the validation of MCH1
as a strong candidate for developing anti-obesity drugs.
Intriguingly, repeated daily MCH1 antagonism by S38151
induced persistent hypermobility in Zucker fa/fa rats, but did not
affect locomotor activity in ob/obmice, and even reduced motility
in DIO mice. The differential response may result from differ-
ences in species (rat vs. mouse) or genetic background (ob/ob
vs. C57BL/6J), or may be related to an off-target mechanism.
When treated with S38151 for 5 days, MCH1-KO mice exhib-
ited a reduction in motility similar to that noted in DIO mice.
Therefore, the observed disparity in motor activity likely arose
from off-target (i.e., MCH1-independent) effects of S38151.
In recent years, MCH1 antagonists have been described as
central to the regulation of energy expenditure and food intake.
However, unlike for neuropeptide Y receptor 5 antagonists [see
Block et al. (2002) and references therein], data suggest that small
molecule antagonists of MCH1 would have much broader activ-
ity, especially regarding mood regulation (and more generally,
depression). Vast programs of drug synthesis and testing have
been published in the literature. One of the surprising key fea-
tures of those programs is that it appeared to be difficult to find
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FIGURE 7 | The effect of repeated daily central administration of MCH to
lean (C57BL/6J) and obese (ob/ob) mice. C57BL/6J (A and B) and ob/ob
(C and D) mice were administered MCH (5μg/mouse/day) or artificial
cerebrospinal fluid vehicle through i.c.v. injections for 5 consecutive days.
Results are expressed as mean ± SEM (n = 10 mice per group). Repeated
measures Two-Way ANOVA (treatment × time) was followed by
complementary analysis of the treatment’s effect at a fixed level of time to
compare all groups of mice with the control group. +P < 0.05.
compounds with potent antagonists against MCH1 that lacked
activity regarding the hERG channel [see Mendez-Andino and
Wos for a complete review (Mendez-Andino andWos, 2007)].
Regarding the onset of obesity, it is well-known that the
adipocyte has a central role, so it seemed interesting to find a
way to act directly upon this cell type. MCH1 is expressed in
adipocytes, suggesting that fat cells may be targets of MCH antag-
onists under physiological conditions (Bradley et al., 2000). This
hypothesis was confirmed by our study using DIO mice treated
with daily S38151 injections for 16 days, in which a reduction in
fat mass was observed concomitant with improvements in glu-
cose and lipid profiles. Indeed, acting through the central control
of appetite has often failed, particularly for two reasons: (1) the
number of “rescue” systems in the brain circuits is so important
that inhibiting one pathway would lead to the “takeover” of one
or several alternate pathways (Nair and Ren, 2009); (2) in some
cases acting on a central system, such as the MCH-ergic system,
to control appetite has promoted adverse effects, and particu-
larly pro-depressive effects (Roy et al., 2007; Lagos et al., 2011;
Garcia-Fuster et al., 2012). Therefore, it was interesting to observe
whether a potent (in the nM range) MCH1 antagonist that was
theoretically incapable of penetrating the blood/brain barrier and
fairly specific (as a derivative of the natural MCH1 agonist MCH)
would have an effect in vivo, as it was already known to be
active i.c.v. (Audinot et al., 2009). S38151 appears to fulfill the
task. Indeed, despite a longer stability than unmodified peptides,
its stability in blood remains too low to expect further reason-
able activity in humans. However, it remains interesting to note
that the blockade of the N-terminus of the peptide with a para-
guanidinobenzoyl moiety may enhance its stability in biological
media.
Furthermore, we were unable to detect traces of this pseu-
dopeptide in the brains of i.p.-injected animals. Similarly, its
effect could not be correlated with aversion owing to a bad test.
Finally, S38151 significantly reduced weight gain in rodent obesity
models, and (most importantly) was inactive in our MCH1-KO
mouse model, strongly suggesting not only the nature of its target
but also its potency and selectivity.
The process through which S38151 induces weight loss
remains poorly understood at the molecular level. We hypothe-
size that it acts locally at the adipocyte level. Indeed, in their paper
on a small, non-peptide antagonist (SCH-A) of MCH1 activity,
Kowalski et al. (2006) performed a careful and complete study
to describe the mechanism of action of this compound at the
adipocyte level. To our knowledge, few peptide MCH agonists
or antagonists have been used in vivo. Indeed, as reviewed by
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FIGURE 8 | The effects of repeated daily S38151 injection on food
and water intake, body weight, and motility in ob/ob mice.
Genetically modified ob/ob mice were administered S38151 (10 and
30mg/kg, i.p.) or vehicle (normal saline i.p.) for 6 consecutive days.
Results are expressed as mean ± SEM (n = 8 mice per group). White
squares for controls, dark squares for 10mg/kg, and dark triangles for
30mg/kg. Repeated measures Two-Way ANOVA (treatment × time) was
followed by complementary analysis of each treatment’s effect at a fixed
level of time to compare all groups of mice with the control group.
*P < 0.05.
FIGURE 9 | The effects of repeated daily S38151 injection on food and
water intake, body weight, and motility in diet-induced obese (DIO)
mice. DIO mice were administered S38151 (10 and 30mg/kg, i.p.) or
vehicle (normal saline i.p.) for 5 consecutive days. Results are expressed as
mean ± SEM (n = 8 mice per group). Repeated measures Two-Way ANOVA
(treatment × time) was followed by complementary analysis of each
treatment’s effect at a fixed level of time to compare all groups of mice with
the control group. *P < 0.05, **P < 0.01, ***P < 0.001.
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FIGURE 10 | The effects of repeated daily S38151 injection on food
and water intake, body weight, and motility in MCHR1-KO mice.
MCH1-KO mice were administered S38151 (10 and 30mg/kg, i.p.) or
vehicle (normal saline i.p.) for 5 consecutive days. Results are expressed
as mean ± SEM (n = 8 mice per group). Repeated measures Two-Way
ANOVA (treatment × time) was followed by complementary analysis of
each treatment’s effect at a fixed level of time to compare all groups of
mice with the control group. *P < 0.05.
Bednarek (2007), peptide ligands at MCH1 were used in vivo by
Mashiko et al. (2005) and Shearman et al. (2003) to demonstrate
the effects of peptide MCH1 antagonists on diet-induced obesity.
Both compounds were administered through i.c.v. injection. To
our knowledge, none of the reported agonists or antagonists was
administered through i.p. injection. The validation of the agonis-
tic nature of MCH, MCH derivatives, or peptides derived from
them, has been reported on several occasions regarding feeding
behavior, and has always involved administration through i.c.v.
injection (Suply et al., 2001) or on their other effects (Chung et al.,
2009; Lagos et al., 2009). All of these data have been reviewed by
MacNeil and Bednarek (2009).
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